论文部分内容阅读
成骨蛋白-1(OP-1)具有很强的骨诱导活性,在许多动物模型中,现已将其用于骨缺损和骨折的治疗。FDA已经批准OP-1putty作为脊柱融合术的载体材料,植入外源性rhOP-1及其载体后,机体可能产生的免疫反应及其他副作用对于成骨蛋白-1在临床应用起了一定的限制作用。本文就其在骨科应用中的安全性进行综述。
Osteogenic protein-1 (OP-1) has a strong osteoinductive activity and has been used in the treatment of bone defects and fractures in many animal models. FDA has approved OP-1putty as a spine fusion carrier material, the implantation of exogenous rhOP-1 and its carrier, the body may have an immune response and other side effects of osteogenic protein-1 in the clinical application of certain restrictions effect. This article reviews its safety in orthopedic applications.